1038916-08-3 Usage
Description
(S)-2-(4-(1-(tert-butoxycarbonyl)piperidin-3-yl)phenyl)-2H-indazole-7-carboxylic acid is a synthetic indazole derivative featuring a carboxylic acid group and a piperidine ring, with a tert-butoxycarbonyl group attached. (S)-2-(4-(1-(tert-butoxycarbonyl)piperidin-3-yl)phenyl)-2H-indazole-7-carboxylicacid's structure indicates its potential pharmaceutical applications, possibly as an inhibitor or modulator of specific biological pathways or receptors. Its exact pharmaceutical potential and applications require further research to be determined.
Uses
Used in Pharmaceutical Industry:
(S)-2-(4-(1-(tert-butoxycarbonyl)piperidin-3-yl)phenyl)-2H-indazole-7-carboxylic acid is used as a potential drug candidate for its possible role as an inhibitor or modulator of biological pathways or receptors. The presence of the tert-butoxycarbonyl group suggests its utility as a protective group in organic synthesis, which could be crucial in the development of new pharmaceuticals.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-2-(4-(1-(tert-butoxycarbonyl)piperidin-3-yl)phenyl)-2H-indazole-7-carboxylic acid is used as a protective group for functional groups during chemical reactions. This application is essential for preventing unwanted side reactions and ensuring the selective formation of desired products in complex synthetic sequences.
Check Digit Verification of cas no
The CAS Registry Mumber 1038916-08-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,8,9,1 and 6 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1038916-08:
(9*1)+(8*0)+(7*3)+(6*8)+(5*9)+(4*1)+(3*6)+(2*0)+(1*8)=153
153 % 10 = 3
So 1038916-08-3 is a valid CAS Registry Number.
1038916-08-3Relevant articles and documents
Derivative based on PARP inhibitor Niraparib and a preparation method and use thereof
-
, (2019/10/29)
The invention discloses a derivative based on a PARP inhibitor Niraparib. The derivative has a structure shown in a formula I as shown in the description, wherein R1 is selected from alkyl, alkoxy, cycloalkyl, aryl alkyl, cycloalkyl alkyl, heterocyclyl, a
Development of a fit-for-purpose large-scale synthesis of an oral PARP inhibitor
Wallace, Debra J.,Baxter, Carl A.,Brands, Karel J. M.,Bremeyer, Nadine,Brewer, Sarah E.,Desmond, Richard,Emerson, Khateeta M.,Foley, Jennifer,Fernandez, Paul,Hu, Weifeng,Keen, Stephen P.,Mullens, Peter,Muzzio, Daniel,Sajonz, Peter,Tan, Lushi,Wilson, Robert D.,Zhou, George,Zhou, Guoyue
, p. 831 - 840 (2012/07/03)
Compound (1) a poly(ADP-ribose)polymerase (PARP) inhibitor has been made by a fit-for-purpose large-scale synthesis using either a classical resolution or chiral chromatographic separation. The development and relative merits of each route are discussed,